Biomarin Pharmaceutical
(NASDAQ:BMRN)
$90.98
-0.53[-0.58%]
Last update: 9:30AM Get Real Time Here
Q1 2024 Earnings in 8 days from now on Wed Apr 24th, after the market close
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest
50%
Overview Rating
Speculative
Technicals Analysis
100
0100
Financials Analysis
20
0100

Biomarin Pharmaceutical Stock (NASDAQ:BMRN), Quotes and News Summary

Biomarin Pharmaceutical Stock (NASDAQ: BMRN) stock price, news, charts, stock research, profile.

Open$90.930
Close-
Volume / Avg.146.023K / 1.388M
Day Range90.160 - 91.130
52 Wk Range76.020 - 100.380
Market Cap$17.266B
P/E Ratio105.195
Dividend Yield-
ExchangeNASDAQ
RSI
62
Short Interest
1.63%
Days to Cover2.74

Recent News

Activist Investor Elliott Pushes for Strategy Revamp at BioMarin Amid CEO Change
Activist investor Elliott Investment Management has taken a significant position in BioMarin Pharmaceutical Inc (NASDAQ: BMRN), engaging with the company on its strategic direction amid leadership changes and the evolving status of its 
Vandana Singh
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session.
Lisa Levin
Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today?
In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a 
Vandana Singh
20%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
Oct 23
5
Nov 23
1
Dec 23
1
Jan
2
Feb
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.0
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell
About Biomarin Pharmaceutical Inc.
Sector
Health Care
Industry
Biotechnology
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme throu...
Show More

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
BMRN
LEGN

FAQ

Q

How do I buy Biomarin Pharmaceutical (BMRN) stock?

A

You can purchase shares of Biomarin Pharmaceutical (NASDAQ: BMRN) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Biomarin Pharmaceutical's (BMRN) competitors?

A

Other companies in Biomarin Pharmaceutical’s space includes: Legend Biotech (NASDAQ:LEGN), Exact Sciences (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Neurocrine Biosciences (NASDAQ:NBIX) and Cerevel Therapeutics Hldg (NASDAQ:CERE).

Q

What is the target price for Biomarin Pharmaceutical (BMRN) stock?

A

The latest price target for Biomarin Pharmaceutical (NASDAQ: BMRN) was reported by Canaccord Genuity on Thursday, February 29, 2024. The analyst firm set a price target for 91.00 expecting BMRN to rise to within 12 months (a possible 0.12% upside). 43 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Biomarin Pharmaceutical (BMRN)?

A

The stock price for Biomarin Pharmaceutical (NASDAQ: BMRN) is $90.895 last updated Today at April 16, 2024 at 10:15 AM EDT.

Q

Does Biomarin Pharmaceutical (BMRN) pay a dividend?

A

There are no upcoming dividends for Biomarin Pharmaceutical.

Q

When is Biomarin Pharmaceutical (NASDAQ:BMRN) reporting earnings?

A

Biomarin Pharmaceutical’s Q1 earnings are confirmed for Wednesday, April 24, 2024.

Q

Is Biomarin Pharmaceutical (BMRN) going to split?

A

There is no upcoming split for Biomarin Pharmaceutical.

Q

What sector and industry does Biomarin Pharmaceutical (BMRN) operate in?

A

Biomarin Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch